Alfred Sandrock - 06 Feb 2026 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Reporting relationship: President and CEO, Director
Issuer ticker: VYGR
Reported as of: 06 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2026, 16:30:53 UTC
Prior SEC filing: 04 Apr 2025
Next SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Gregory Shiferman, as Attorney-in-Fact for Alfred Sandrock

Key filing fact

Alfred Sandrock filed Form 4 for Voyager Therapeutics, Inc. (VYGR) on 10 Feb 2026.

Key facts

This page summarizes Alfred Sandrock's Form 4 filing for Voyager Therapeutics, Inc. (VYGR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Feb 2026, 16:30.

Change

Previous filing in this sequence was filed on 04 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001577061 Primary reporting owner

Sandrock Alfred

Relationship: President and CEO, Director
Address: C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON
Signature: /s/ Gregory Shiferman, as Attorney-in-Fact for Alfred Sandrock
Signature date: 10 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYGR transaction

Common Stock

Award

Transaction value: $0
Shares: +86,250
Change %: +20%
Price: $0.000000
Shares after: 522,181
Date: 06 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +402,500
Change %
Price: $0.000000
Shares after: 402,500
Date: 06 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 402,500
Exercise price: $3.68
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of shares of common stock issuable under an aggregate of 86,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

Footnote F2

Includes 5,000 shares of common stock acquired under the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.

Footnote F3

This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.